TAVR Indications and Guidelines

Patient Selection and Evaluation

• The American College of Cardiology recommends TAVR for symptomatic severe aortic stenosis with any symptoms related to aortic stenosis, regardless of surgical risk when anatomically suitable 1
• The European Society of Cardiology suggests TAVR for severe aortic stenosis with left ventricular systolic dysfunction (LVEF <50%) not due to another cause 2, 1
• TAVR is recommended for severe aortic stenosis in patients undergoing coronary artery bypass grafting, ascending aorta surgery, or another valve surgery 2, 1
• Asymptomatic severe aortic stenosis with abnormal exercise test showing symptoms clearly related to aortic stenosis is an indication for TAVR 1
• Suitable aortic and vascular anatomy for TAVR access is a critical selection criterion 3, 1
• Predicted survival >12 months is required to justify TAVR intervention 3, 1
• Trileaflet aortic valve with severe, symptomatic, calcific stenosis is a traditional indication for TAVR 3

Diagnostic Thresholds

• High-gradient severe aortic stenosis is defined as AVA ≤1.0 cm² with peak velocity ≥4 m/s or mean gradient ≥40 mmHg 1
• Very severe aortic stenosis is defined as peak velocity ≥5 m/s or mean gradient ≥60 mmHg 1
• Extremely severe aortic stenosis is defined as AVA ≤0.6 cm², mean gradient ≥50 mmHg, or jet velocity ≥5 m/s 1
• Low-flow, low-gradient severe aortic stenosis is defined as AVA ≤1.0 cm² with peak velocity <4 m/s or mean gradient <40 mmHg 1

Procedural Considerations

• Multidisciplinary Heart Valve Team evaluation is foundational and mandatory for all TAVR decisions, involving interventional cardiology, cardiac surgery, imaging specialists, and heart failure specialists 3, 4, 5, 1
• Team-based decision-making is particularly critical given the complex technology and multiple interlocking procedural steps 3, 4
• Meticulous attention to procedural steps is essential given the complex technology and multiple interlocking components 3, 4

Monitoring and Follow-up

• Regular clinical evaluation every 6-12 months is recommended for asymptomatic severe aortic stenosis 1
• Serial echocardiography is necessary to monitor disease progression 1
• Exercise testing is used to unmask symptoms or abnormal hemodynamic responses 1
• Earlier intervention should be considered with rapid progression (velocity increase >0.3 m/s/year) or very severe aortic stenosis 1

Comparative Outcomes

• TAVR demonstrates superior or equivalent short-term mortality (0-5% vs. 1.7-3% for surgical aortic valve replacement) 3
• Stroke rates are 0-7% with TAVR vs. 0.6-2% with surgical aortic valve replacement, with higher early ischemic events but improved with newer techniques 3
• Access complications occur in 17% of TAVR patients (primarily vascular) 3
• Pacemaker requirements vary significantly by valve type and patient anatomy, ranging from 2-43% depending on valve type 3

Indications for Transcatheter Aortic Valve Replacement (TAVR)

Symptomatic Severe Aortic Stenosis

The American College of Cardiology (ACC) considers any classic symptom attributable to severe aortic stenosis an indication for TAVR when anatomy is suitable.

Selected Asymptomatic Severe Aortic Stenosis

The ACC identifies specific asymptomatic scenarios in which TAVR (or surgical AVR) may be appropriate.

Surgical Risk Stratification for TAVR Eligibility

The ACC defines operative risk categories that guide TAVR decision‑making.

(Higher‑risk categories are described in the source but lack explicit citations and are therefore omitted.)

Evidence Supporting Expansion to Low‑Risk Patients

Regulatory approval (FDA) for TAVR in low‑risk patients is based on data from the PARTNER 3 and Evolut Low‑Risk trials.